
The CF Foundation was actually in the news this week, after receiving a $3.3 billion (yes, billion with a B) payout from the sale of future royalty rights to the portfolio of CF drugs being developed by Vertex. In what is now called "venture philanthropy," the CFF gave money to Vertex to finance the development of CF drugs, with the agreement that the CFF would get a share of the royalties on any drugs developed. The first such drug, Kalydeco, is now on the market and many more exciting medicines are coming along in the pipeline. Rather than wait for the royalties to trickle in over the next 20 years, the CFF sold the rights to the royalties to an investment firm so it could have access to all the cash right away. The money can now be reinvested in further research, and the other services that the CFF provides to CF patients. Although some have questioned the CFF's for possible conflict of interest(the cost of Kalydeco is currently $300,000/year, and the high price might be related to the high value of the royalties), my feeling is that this is pretty much a huge win for the CF community. After all, what other rare disease right now has a $3.3 billion research budget? I feel like if it's possible to buy enough research to find drugs for all CF patients, money won't be our limitation now. So much progress has been made in the last decade, and I'm excited to see what this new bolus of funding will bring in the decade to come.